NASDAQ
1.32USD
+0.03 (+2.33%)
We have scored 7 news catalysts on Cassava Sciences, Inc. (SAVA) over the past 12 months. The biggest single-day move next to one of them came Apr 6, 2026, when SAVA closed −12.2%: “Jamie Dimon warns Iran war could drive inflation, interest rates higher”. Coverage across the window leans negative (average ticker sentiment −0.91). Most of the impact sits in revenue cyclicality and geographic supply risk.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
63.8M
P/E
—
EPS
—
Beta
-0.84
52W range
1.15-4.98
Day range
1.27–1.34
Open
1.30
Prev close
1.29
Volume
134.3K
Avg volume
375.8K
Dividend
0.00
IPO
2000-07-14
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Cassava Sciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SAVA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.
